Literature DB >> 16926356

Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States.

Fujie Xu1, Maya R Sternberg, Benny J Kottiri, Geraldine M McQuillan, Francis K Lee, Andre J Nahmias, Stuart M Berman, Lauri E Markowitz.   

Abstract

CONTEXT: Herpes simplex virus type 1 (HSV-1) and type 2 are common infections worldwide. Herpes simplex virus type 2 (HSV-2) is the cause of most genital herpes and is almost always sexually transmitted. In contrast, HSV-1 is usually transmitted during childhood via nonsexual contacts. Preexisting HSV-1 antibodies can alleviate clinical manifestations of subsequently acquired HSV-2. Furthermore, HSV-1 has become an important cause of genital herpes in some developed countries.
OBJECTIVE: To examine trends in HSV-1 and HSV-2 seroprevalence in the United States in 1999-2004 compared with 1988-1994. DESIGN, SETTINGS, AND PARTICIPANTS: Cross-sectional, nationally representative surveys (US National Health and Nutrition Examination Surveys [NHANES]), were used to compare national seroprevalence estimates from 1999-2004 with those from 1988-1994, and changes in HSV-1 and HSV-2 seroprevalence since 1976-1980 were reviewed. Persons aged 14 to 49 years were included in these analyses. MAIN OUTCOME MEASURES: Seroprevalence of HSV-1 and HSV-2 antibodies based on results from type-specific immunodot assays; diagnosis of genital herpes.
RESULTS: The overall age-adjusted HSV-2 seroprevalence was 17.0% (95% confidence interval [CI], 15.8%-18.3%) in 1999-2004 and 21.0% (95% CI, 19.1%-23.1%) in 1988-1994, a relative decrease of 19.0% between the 2 surveys (95% CI, -28.6% to -9.5%; P<.001). Decreases in HSV-2 seroprevalence were especially concentrated in persons aged 14 to 19 years between 1988 and 2004. In adolescents aged 17 to 19 years and young adults, the decreases in HSV-2 seroprevalence were significant even after adjusting for changes in sexual behaviors. Among those infected with HSV-2, the percentage who reported having been diagnosed with genital herpes was statistically different (14.3% in 1999-2004 and 9.9% in 1988-1994; P = .02). Seroprevalence of HSV-1 decreased from 62.0% (95% CI, 59.6%-64.6%) in 1988-1994 to 57.7% (95% CI, 55.9%-59.5%) in 1999-2004, a relative decrease of 6.9% between the 2 surveys (95% CI, -11.6% to -2.3%; P = .006). Among persons infected with HSV-1 but not with HSV-2, a higher percentage reported having been diagnosed with genital herpes in 1999-2004 compared with 1988-1994 (1.8% vs 0.4%, respectively; P<.001).
CONCLUSIONS: These data show declines in HSV-2 seroprevalence, suggesting that the trajectory of increasing HSV-2 seroprevalence in the United States has been reversed. Seroprevalence of HSV-1 decreased but the incidence of genital herpes caused by HSV-1 may be increasing.

Entities:  

Mesh:

Year:  2006        PMID: 16926356     DOI: 10.1001/jama.296.8.964

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  344 in total

1.  Herpes diagnostic tests and their use.

Authors:  Nicholas J Van Wagoner; Edward W Hook
Journal:  Curr Infect Dis Rep       Date:  2012-04       Impact factor: 3.725

Review 2.  Slipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistance.

Authors:  Anthony Griffiths
Journal:  Drug Resist Updat       Date:  2011-09-22       Impact factor: 18.500

Review 3.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

4.  CD8+ T cells suppress viral replication in the cornea but contribute to VEGF-C-induced lymphatic vessel genesis.

Authors:  Christopher D Conrady; Min Zheng; Donald U Stone; Daniel J J Carr
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

5.  Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.

Authors:  Sita Awasthi; John W Balliet; Jessica A Flynn; John M Lubinski; Carolyn E Shaw; Daniel J DiStefano; Michael Cai; Martha Brown; Judith F Smith; Rose Kowalski; Ryan Swoyer; Jennifer Galli; Victoria Copeland; Sandra Rios; Robert C Davidson; Maya Salnikova; Susan Kingsley; Janine Bryan; Danilo R Casimiro; Harvey M Friedman
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

6.  The STING agonist 5,6-dimethylxanthenone-4-acetic acid (DMXAA) stimulates an antiviral state and protects mice against herpes simplex virus-induced neurological disease.

Authors:  Stacey Cerón; Brian J North; Sean A Taylor; David A Leib
Journal:  Virology       Date:  2019-01-06       Impact factor: 3.616

7.  Neonatal herpes simplex virus infection.

Authors:  Thomas L Cherpes; Dean B Matthews; Samantha A Maryak
Journal:  Clin Obstet Gynecol       Date:  2012-12       Impact factor: 2.190

8.  Behavioral, Psychological, Gender, and Health Service Correlates to Herpes Simplex Virus Type 2 Infection among Young Adult Mexican-American Women Living in a Disadvantaged Community.

Authors:  Kathryn M Nowotny; Jessica Frankeberger; Victoria E Rodriguez; Avelardo Valdez; Alice Cepeda
Journal:  Behav Med       Date:  2018-05-09       Impact factor: 3.104

9.  Prevalence and Correlates of Trichomonas vaginalis Infection Among Men and Women in the United States.

Authors:  Eshan U Patel; Charlotte A Gaydos; Zoe R Packman; Thomas C Quinn; Aaron A R Tobian
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

10.  Discrimination of antibody to herpes B virus from antibody to herpes simplex virus types 1 and 2 in human and macaque sera.

Authors:  Akikazu Fujima; Yoshitsugu Ochiai; Aya Saito; Yuki Omori; Atsuya Noda; Yukumasa Kazuyama; Hiroshi Shoji; Kiyoshi Tanabayashi; Fukiko Ueda; Yasuhiro Yoshikawa; Ryo Hondo
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.